Feb. 12 at 3:03 PM
th2 immune movers & the extended dosing battle:
$UPB valiant data & the dosing dilemma yesterday’s phase 2 valiant results for verekitug were a "win" on efficacy but a "loss" on market expectations. while the drug matched tezspire’s efficacy with an impressive q12w (quarterly) dosing regimen (56% aaer reduction), the -47.18% plunge in share price confirms that the market was banking on the q24w (biannual) dose being the primary differentiator. the drop to a 39% reduction at 24 weeks has created a massive valuation gap—potentially a prime dip-buying opportunity since the quarterly profile may be enough to disrupt the market. of course, there are other next gen extended dosing opportunities also in development.
$ACRS : the pipeline continues to look robust. keep an eye on the upcoming phase 1b tslp-il4 bispecific (ati-052) data, which aims to provide a "best-in-class" dual mechanism for both asthma and atopic dermatitis.
$PALI : we are still looking for the fscd readout in 1h 2026. the team remains active in the conference circuit, recently participating in the piper sandler virtual novel targets in immunology symposium.
$NKTR : their recent rezolve-ad maintenance data showed durable responses, but the price pop may be overextended. the patient population in the study was relatively "easier" to treat (less experienced) and enriched in maintenance portion, so i'd remain cautious here despite the hype. the mgmt team here is not the most reliable.
$CRVS : i still prefer the soquelitinib oral play for ad. their recent cohort 4 data confirmed strong results in a placebo-controlled setting in a more difficult refractory patient population, and the team’s execution has been top-tier.
